Funding a First Production Run

Almost every first production run is under-budgeted in the same way: the inventor funds the goods and forgets the gap. Tooling and units are visible, quotable and easy to plan for. The four to five months between paying a factory deposit and receiving payment from a retailer is invisible until it arrives, and it is the reason profitable products run out of money.

Funding an invention through to its first shipped units is therefore two separate problems. The first is capital expenditure — moulds, samples, certification, artwork — which is spent once and does not come back. The second is working capital, which is spent, recovered, and spent again on every cycle, growing in proportion to sales. Confusing the two produces a budget that looks adequate and fails at the second order.

Requirement · The Number

What a First Run Actually Costs

Price the whole thing before choosing a source, because funding an invention is a question that cannot be answered until the requirement is known to the nearest few thousand. For a moulded consumer product at a landed unit cost near $3.20, a realistic first-run budget breaks down as follows: design for manufacture and sampling at $4,000 to $15,000; injection tooling at $12,000 to $45,000 depending on cavity count and finish; safety, compliance and materials testing at $2,000 to $12,000 depending on category; packaging design, artwork and barcodes at $1,500 to $6,000; and the goods themselves at a factory minimum order quantity of 3,000 to 10,000 units, which is $10,000 to $32,000 of stock.

• $32k – $110kAll-in first-run budget for a moulded consumer product, tooling through landed stock
• 4 – 5 moGap between the factory deposit and payment from a retailer on net-sixty terms
• 15% – 25%Contingency that experienced operators add before signing anything

That totals somewhere between $30,000 and $95,000 before a single unit is sold, and before freight, duty, insurance and warehousing. Add a contingency of fifteen to twenty-five per cent, because first tools almost always need a revision and first samples almost always reveal something. The payment schedule matters as much as the total: factories commonly ask thirty per cent of the tooling cost on order and the balance on approval, then thirty per cent of the goods on order with the remainder before shipment. Very little of that is deferrable.

Set against the alternative, the figure is worth stating plainly. Licensing the same invention would have cost nothing beyond the patent itself. This is the number that makes the trade-off between licensing and building a treasury decision rather than a preference, and it is why the capital question should be priced before the route is chosen rather than after.

Sources · Own Money

Savings, Credit and the Staged Run

Most first runs are self-funded, and the reason is not ideology. Every external source of money either wants security an inventor cannot give, a trading history that does not exist, or a share of an asset whose value has not yet been established. Savings are slow but they are the only capital with no covenants attached.

The discipline that makes self-funding survivable is staging. Rather than committing $60,000 at once, break the run into gates: $3,000 for a functional prototype and a verified quote; $6,000 for a soft tool or bridge-process run of 200 to 500 units; then, only if the sell-through data holds, $30,000 for hard tooling and a full minimum order. Each gate has an explicit pass condition written before the money is spent. A soft tool costs a fraction of a production mould and yields a few hundred to a couple of thousand parts — enough to test everything except unit economics at scale.

Consumer credit deserves a blunt note. Revolving credit at twenty to twenty-nine per cent annualised, used to finance stock that turns over in five months, costs roughly nine to twelve per cent of the goods value per cycle — which on a product with a fifteen per cent net margin consumes most of the profit. It is viable only as a bridge with a defined repayment event, never as the base layer. Secured borrowing against a home converts a business risk into a housing risk, and the asymmetry of that trade is the single most common serious error in this field.

Grants and competitions are worth an hour of research and rarely more. Where innovation grants exist in a given territory they are usually tied to research activity, matched funding or employment, and application cycles run three to nine months — useful for a development phase, almost never useful for stock. Treat any grant as a bonus that arrives after the decision, not an input to it.

Sources · Other People's Money

Pre-Orders, Purchase Orders and Factoring

Three instruments finance the goods without selling equity, and all three depend on demand that can be evidenced.

Pre-selling is the strongest of them, because the buyer's money arrives before the factory's invoice does. A crowdfunding campaign or a direct pre-order list converts the working-capital gap into a positive balance, and it simultaneously produces the demand evidence every other funder wants to see. The costs are real: platform and payment fees of eight to ten per cent, campaign assets and advertising that commonly run $5,000 to $25,000, and an obligation to ship that becomes reputationally expensive if the factory slips. The failure mode is specific and common — funding at a price set before the final landed cost is known, then shipping at a loss on every unit.

Purchase-order finance applies once a creditworthy buyer has issued an actual order. A lender pays the supplier directly against that order, typically advancing seventy to ninety per cent of the cost and charging one and a half to three per cent per thirty days, which annualises to roughly eighteen to thirty-six per cent. Expensive in headline terms, and often the right instrument anyway, because it is priced against a confirmed order rather than a forecast and it does not touch ownership. Invoice factoring performs the same function one step later, advancing seventy to ninety per cent of an issued invoice at one to three per cent a month, which turns net-sixty terms into near-immediate cash.

There is a fourth option that costs nothing at all and is regularly overlooked: the licensee advance. An advance of $5,000 to $25,000 against future royalties is capital that never has to be repaid in cash, only earned out against income. Where a product can plausibly be licensed, that route funds itself by definition. Detailed accounts of independent products reaching market, such as the reporting on how the MixAid device moved from concept to production and the inventors' own version in this walkthrough of the invention's development, are useful chiefly for what they show about sequence: the funding question is usually settled by which route the product suits, not by which cheque is easiest to obtain.

Sources · Equity

What Selling a Share Actually Costs

Friends, family and small private investors fund a meaningful share of first runs, and equity is the most expensive money available when the product works. Selling twenty-five per cent of a venture for $40,000 values the whole thing at $160,000 at the moment of least information. If the product reaches $500,000 of annual revenue three years later, that quarter share is worth several times what it cost, and it cannot be bought back at the original price.

Two structures reduce the damage. A convertible loan, repayable with interest but convertible to equity at the investor's option if a later round happens, defers the valuation question until there is evidence to price it. A revenue share — a fixed percentage of sales paid until an agreed multiple of the original amount has been returned, commonly one and a half to two and a half times — puts a ceiling on the cost and returns full ownership at the end. Either is usually better than a permanent equity slice sold at the earliest and worst moment.

Whatever the instrument, three things must be written down before money changes hands, particularly with family. What happens if the run sells out and a second is needed. What happens if it does not sell and the stock has to be liquidated. Who owns the patent itself, as distinct from the business trading under it — the usual and correct answer being that the invention is licensed to the venture rather than assigned to it, so that a failed trading entity does not take the underlying right with it. The size of any equity ask should also be sanity-checked against what the underlying right is currently worth, since selling a share of a venture is implicitly selling a share of that asset.

A note on ordering. The sequence that survives contact with reality funds evidence before it funds volume: own money for the prototype and the verified quote, pre-orders or an advance for the goods, purchase-order finance or factoring for growth once orders exist, and equity only if a genuinely capital-hungry opportunity appears that none of the earlier layers can reach. Reversing that order — raising equity first because it feels like progress — sells the most valuable thing at the worst moment.

Discipline · The Stop

Deciding in Advance When to Stop

Funding an invention responsibly means writing the abandonment conditions at the same time as the budget, while the decision is still cheap and nobody is defending three years of sunk cost. Four stops are worth naming explicitly: a tooling quote returning at more than double the modelled figure; a landed cost that leaves less than a 2.5-times markup to wholesale; no reorder from the first buyers within ninety days of the pilot run; and a total spend reaching the pre-agreed ceiling regardless of how close the next milestone appears.

Each of those is a number that can be written on one line today. Their value is that they convert a future emotional decision into a present arithmetic one. Abandonment decided in advance is a budget line; abandonment decided after the money is gone is a loss defended long past the point of sense, because by then the cost is not only financial. The same logic sits behind the outlay-and-return ledger for the whole project: the discipline that saves the most money is deciding the exit before the entry.

It is also worth being realistic about what capital cannot fix. Money accelerates a product that works and it accelerates the failure of one that does not. Broad practical overviews of the path from concept to shelf, including this step-by-step guide to turning invention ideas into finished products, consistently place the funding decision after cost verification and demand evidence rather than before — and case reporting on products that reached market, such as the account of a vibration-based pain relief product finding its category, tends to describe the same order of operations.

None of this makes the first run safe. It makes the exposure known, staged and bounded, which is the most an individual can reasonably ask of a decision this size.

Price the gap, not just the goods; fund evidence before volume; and write down the stop before the first deposit leaves the account.